T1	Participants 374 395	human tumour necrosis
T2	Participants 564 845	15 subjects with inflammatory arthritis (14 with rheumatoid arthritis and 1 with ankylosing spondylitis) not receiving tumour necrosis factor alpha (TNFalpha) inhibitors with persistent moderate (grade 2) or severe (grade 3) swelling in a target joint due to inflammatory arthritis
T3	Participants 447 483	subjects with inflammatory arthritis
